Phospho-WEE1 (Ser642) Antibody

What is WEE1 and what role does phosphorylation at Ser642 play in its function?

WEE1 is a nuclear protein kinase that acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis . WEE1 mediates phosphorylation of CDK1 on Tyr-15, specifically phosphorylating and inactivating cyclin B1-complexed CDK1 .

Phosphorylation at Ser642 is a critical regulatory mechanism affecting WEE1 function. Akt/PKB-dependent phosphorylation at Ser642 promotes a change in WEE1 localization from nuclear to cytoplasmic and is associated with G2/M arrest . WEE1's activity increases during S and G2 phases and decreases at M phase when it becomes hyperphosphorylated . The phosphorylation status at Ser642 thus serves as an important indicator of WEE1 activation state within the cell cycle.

What are the key specifications of commercially available Phospho-WEE1 (Ser642) antibodies?

Most commercially available Phospho-WEE1 (Ser642) antibodies share several common specifications:

These antibodies are specifically designed to detect WEE1 protein only when phosphorylated at Ser642, making them valuable tools for studying the activation state of WEE1 in various cellular contexts .

What experimental applications are most suitable for Phospho-WEE1 (Ser642) antibodies?

Phospho-WEE1 (Ser642) antibodies have been validated for multiple experimental applications, each with specific advantages:

Western Blotting (WB): The most common application, allowing quantitative assessment of phospho-WEE1 levels. Typical dilutions range from 1:500-1:2000 . The observed band appears at approximately 95-100 kDa. Sample preparation should include phosphatase inhibitors to preserve phosphorylation status.

Immunoprecipitation (IP): Useful for enriching phospho-WEE1 from complex lysates. Recommended dilution is approximately 1:50 . This approach can be combined with mass spectrometry for detailed analysis of WEE1 phosphorylation sites.

Immunohistochemistry (IHC): Enables visualization of phospho-WEE1 localization in tissue sections. For paraffin-embedded sections (IHC-P), dilutions of 1:200-1:400 are recommended; for frozen sections (IHC-F), 1:100-1:500 .

Immunofluorescence/Immunocytochemistry (IF/ICC): Allows subcellular localization studies. Typical dilutions range from 1:50-1:200 .

ELISA: Provides quantitative measurement of phospho-WEE1 levels. Cell-based ELISA kits are particularly useful for high-throughput screening of compounds affecting WEE1 phosphorylation status .

What are the recommended protocols for optimizing Western blot detection of phospho-WEE1 (Ser642)?

Detecting phospho-WEE1 (Ser642) by Western blotting requires careful attention to sample preparation and experimental conditions:

• Sample preparation:

  • Harvest cells rapidly to preserve phosphorylation status

  • Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) in lysis buffers

  • Use gentle lysis conditions to preserve protein integrity

  • Maintain samples at 4°C throughout processing

• Gel electrophoresis and transfer:

  • Use 8-10% polyacrylamide gels to adequately resolve the ~95-100 kDa WEE1 protein

  • Transfer proteins to PVDF or nitrocellulose membranes at lower voltages (e.g., 30V overnight) to ensure complete transfer of larger proteins

• Antibody incubation:

  • Block membranes thoroughly (5% BSA in TBST is often preferred over milk for phospho-epitopes)

  • Incubate with primary antibody (1:500-1:2000 dilution) overnight at 4°C

  • Use high-quality secondary antibodies with minimal cross-reactivity

• Controls and validation:

  • Include positive controls (e.g., cells treated with DNA damaging agents that activate WEE1)

  • Use lambda phosphatase-treated lysates as negative controls

  • Consider using WEE1 knockdown/knockout samples to confirm specificity

Following these protocols will help ensure specific and sensitive detection of phospho-WEE1 (Ser642) in your experimental system .

How can researchers validate the specificity of phospho-WEE1 (Ser642) antibody detection?

Validating antibody specificity is crucial for accurate interpretation of results. For phospho-WEE1 (Ser642) antibodies, consider these validation approaches:

• Phosphatase treatment: Treat a portion of your lysate with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show diminished or absent signal in treated samples.

• Peptide competition assays: Pre-incubate the antibody with the phospho-peptide immunogen [SV(p-S)LT] before adding to your membrane or cells. This should block specific binding and reduce signal.

• Genetic validation: Use WEE1 knockdown (siRNA or shRNA) or knockout (CRISPR-Cas9) samples as controls. No signal should be detected in these samples.

• Biological validation: Compare samples with known differences in WEE1 phosphorylation status. For example, cells in G2 phase should show higher levels of phospho-WEE1 (Ser642) compared to cells in M phase.

• Multiple antibody comparison: If possible, use phospho-WEE1 (Ser642) antibodies from different vendors or clones that recognize the same epitope to confirm your results.

These approaches provide complementary evidence for antibody specificity and help eliminate false positive results in your research .

How does phosphorylation at Ser642 regulate WEE1 activity in cell cycle control and cancer?

The phosphorylation status of WEE1 at Ser642 plays a sophisticated role in regulating cell cycle progression:

Ser642 phosphorylation affects both WEE1 localization and activity. Akt/PKB-dependent phosphorylation at this site promotes relocalization of WEE1 from the nucleus to the cytoplasm and is associated with G2/M arrest . This phosphorylation event represents one of the multiple regulatory mechanisms controlling WEE1 function during cell cycle progression.

In cancer contexts, WEE1 phosphorylation status becomes particularly important. Cancer cells often have defective G1 checkpoints and rely heavily on the G2/M checkpoint for DNA repair. Phospho-WEE1 (Ser642) levels can indicate the activation state of this critical checkpoint . The ability to monitor phospho-WEE1 (Ser642) provides insights into how cancer cells respond to DNA damaging agents and checkpoint inhibitors.

Research has shown that in polarized neurons, phosphorylation of Ser642 by brain-selective kinases BRSK1 and BRSK2 can down-regulate WEE1 activity . This finding suggests that the same phosphorylation site may have context-dependent effects, potentially regulated by different upstream kinases in different cell types.

What is the significance of WEE1 activation in resistance to PI3K inhibition in cancer therapy?

Recent research has revealed that WEE1 activation contributes to adaptive resistance mechanisms against PI3K inhibitors in cancer treatment:

A study with glioblastoma cells demonstrated that WEE1 is activated after 24 hours of treatment with the PI3K inhibitor buparlisib (BKM120), as evidenced by decreased phosphorylation of WEE1-Ser642 . This activation represents an adaptive response that allows cancer cells to survive PI3K inhibition.

The mechanism involves activated WEE1 phosphorylating Cdc2 (CDK1), which inactivates Cdc2 and leads to G2/M arrest . This cell cycle arrest provides cancer cells with time to adapt to PI3K inhibition and develop resistance.

Importantly, WEE1 inhibition by small-molecule inhibitors can abrogate this PI3K inhibition-induced G2/M arrest, forcing cells into premature mitosis and consequent cell death . This finding suggests a potential therapeutic strategy combining PI3K and WEE1 inhibitors to overcome resistance mechanisms in glioblastoma and potentially other cancers.

The ability to monitor phospho-WEE1 (Ser642) levels using specific antibodies provides a valuable biomarker for tracking this resistance mechanism and evaluating the efficacy of combination therapies targeting both PI3K and WEE1.

How can phospho-WEE1 (Ser642) antibodies be used to study the relationship between WEE1 inhibition and immune responses?

Emerging research has revealed unexpected connections between WEE1 inhibition and antitumor immune responses that can be studied using phospho-WEE1 (Ser642) antibodies:

WEE1 inhibition has been shown to enhance antitumor immune responses to PD-L1 blockade through activation of STING and STAT1 pathways in small cell lung cancer (SCLC) . This finding connects cell cycle regulation with immune system activation.

The mechanism involves WEE1 inhibition leading to increased micronuclei formation and cytosolic DNA, which activates the cGAS/STING pathway . This activation induces expression of type I interferons and inflammatory chemokines, enhancing immune responses against cancer cells.

Researchers can use phospho-WEE1 (Ser642) antibodies to:

• Monitor WEE1 activation status during treatment with WEE1 inhibitors

• Correlate changes in WEE1 phosphorylation with downstream immune pathway activation

• Identify cell types with differential WEE1 phosphorylation responses

• Develop biomarkers for predicting response to combined immune checkpoint and WEE1 inhibitor therapies

This application represents an advanced use of phospho-WEE1 (Ser642) antibodies that bridges cell cycle research with immunology and cancer therapy.

What are the technical considerations for studying multiple phosphorylation sites in WEE1?

WEE1 contains multiple phosphorylation sites that collectively regulate its function. Studying these sites presents specific technical challenges:

Comprehensive phosphorylation analysis: Full-length WEE1 has been found to be phosphorylated at 25 different residues, with 10 located in the kinase domain, while phosphorylation patterns differ between Wee1, Wee2, and Myt1 family members . This complexity requires careful experimental design.

Site-specific antibodies: While Ser642 is an important phosphorylation site, researchers should consider other key sites. For example, Wee1 and Wee2 share a strictly conserved phosphorylated residue (Ser642 and Ser557, respectively), while Wee1 and Myt1 share two phosphorylation sites: Tyr325/Tyr136 and Ser472/Thr260 .

Multiplexed detection approaches: Consider using:

• Multiple Western blots with site-specific phospho-antibodies

• Mass spectrometry-based phosphoproteomics for comprehensive site mapping

• Phospho-flow cytometry for single-cell analysis of key phosphorylation sites

Kinase-substrate relationships: Different kinases may target specific WEE1 phosphorylation sites. For example, Ser642 has been reported as a target of brain-selective kinases BRSK1 and BRSK2 in neurons , while different kinases may phosphorylate this site in other contexts.

Temporal dynamics: Different phosphorylation events may occur in sequence or with different kinetics. Time-course experiments with phospho-specific antibodies can reveal these relationships.

Understanding the interplay between multiple phosphorylation events requires integrating data from site-specific antibodies with broader phosphoproteomic approaches to build a comprehensive model of WEE1 regulation.

How can phospho-WEE1 (Ser642) antibodies be used to evaluate WEE1 inhibitor efficacy in cancer research?

Phospho-WEE1 (Ser642) antibodies provide valuable tools for evaluating WEE1 inhibitor efficacy across multiple experimental contexts:

In vitro drug screening: Cell-based ELISA kits using phospho-WEE1 (Ser642) antibodies enable high-throughput screening of compounds that affect WEE1 phosphorylation status . This allows rapid identification of potential WEE1 inhibitors.

Mechanism of action studies: Western blotting with phospho-WEE1 (Ser642) antibodies can confirm that WEE1 inhibitors are engaging their target. Changes in phosphorylation status at Ser642 can indicate altered WEE1 activation and provide insights into inhibitor mechanisms .

Pharmacodynamic biomarkers: In preclinical models and potentially clinical samples, phospho-WEE1 (Ser642) levels can serve as pharmacodynamic biomarkers. Monitoring changes in phosphorylation following drug treatment provides evidence of target engagement in vivo .

Resistance mechanism identification: By tracking phospho-WEE1 (Ser642) levels in cells developing resistance to WEE1 inhibitors, researchers can identify adaptive responses and develop strategies to overcome resistance .

Combination therapy development: Phospho-WEE1 (Ser642) antibodies can help evaluate how WEE1 inhibitors interact with other targeted therapies. For example, combining WEE1 inhibitors with PI3K inhibitors shows promise in overcoming resistance mechanisms in glioblastoma .

What are the methods for analyzing WEE1 phosphorylation status in tumor samples?

Analyzing WEE1 phosphorylation in clinical tumor samples presents unique challenges that require specialized approaches:

Tissue preservation: Phosphorylation status can rapidly change ex vivo. Use rapid freezing of tissues or specialized fixatives containing phosphatase inhibitors to preserve phospho-epitopes.

IHC optimization: For immunohistochemical detection:

• Use antigen retrieval methods optimized for phospho-epitopes

• Employ tyramide signal amplification to enhance sensitivity

• Include appropriate positive and negative controls in each batch

• Consider dual staining with total WEE1 antibodies to normalize phospho-signal

Validation approaches:

• Compare phospho-WEE1 (Ser642) levels between matched normal and tumor tissues

• Correlate with markers of cell cycle phase and DNA damage response

• Validate IHC findings with orthogonal methods like Western blot when sufficient material is available

Quantification methods:

• Use digital pathology systems for consistent scoring

• Develop H-score or Allred scoring systems appropriate for phospho-WEE1 (Ser642)

• Consider machine learning approaches for automated quantification

Patient-derived models: When direct analysis of tumor samples is challenging, consider:

• Patient-derived xenografts to maintain tumor architecture

• Ex vivo organoid cultures for functional studies while preserving tissue context

• Primary cell cultures with minimal passage to limit phosphorylation changes

These methodological considerations help ensure reliable analysis of WEE1 phosphorylation status in clinical samples, potentially supporting biomarker development for WEE1-targeted therapies.

What emerging roles of WEE1 phosphorylation at Ser642 are being investigated beyond cell cycle control?

Research is uncovering novel functions of phosphorylated WEE1 beyond its canonical role in cell cycle regulation:

Neuronal development: Phosphorylation of WEE1 at Ser642 by brain-selective kinases BRSK1 and BRSK2 regulates WEE1 activity in polarized neurons during the establishment of distinct axonal and dendritic compartments . This finding connects WEE1 phosphorylation to neuronal development and morphogenesis.

DNA damage response signaling: WEE1 inhibition activates the cGAS/STING pathway and induces expression of type I interferons and inflammatory chemokines . This suggests potential roles for phospho-WEE1 in modulating DNA damage-induced immune responses.

Epigenetic regulation: WEE1 has been reported to phosphorylate histone H2B at Tyr37, suppressing histone transcription in late S phase and providing a direct link between epigenetics and cell-cycle progression . The relationship between Ser642 phosphorylation and this epigenetic function remains to be fully elucidated.

Cancer stem cell maintenance: Emerging evidence suggests WEE1 may play roles in cancer stem cell biology, with phosphorylation status potentially regulating stemness properties. Phospho-WEE1 (Ser642) antibodies could help investigate these connections.

Metabolic regulation: The intersection between cell cycle checkpoints and cellular metabolism is an active area of research. WEE1 phosphorylation status may integrate cell cycle progression with metabolic cues, representing an exciting frontier for investigation.

These emerging areas highlight the importance of phospho-WEE1 (Ser642) antibodies as versatile tools for exploring WEE1 functions beyond traditional cell cycle control.

How might advanced proteomic approaches complement antibody-based detection of phospho-WEE1 (Ser642)?

While antibody-based detection of phospho-WEE1 (Ser642) remains invaluable, emerging proteomic approaches offer complementary advantages:

Mass spectrometry-based phosphoproteomics:

• Enables simultaneous detection of multiple WEE1 phosphorylation sites

• Allows quantitative comparison of phosphorylation levels across different sites

• Can identify novel phosphorylation sites and their relative abundances

• Provides unbiased assessment of phosphorylation changes in the entire proteome

Proximity labeling proteomics:

• BioID or APEX2 fusions to WEE1 can identify proteins in proximity to WEE1

• Changes in the WEE1 interactome based on Ser642 phosphorylation status can be detected

• Helps map the functional consequences of phosphorylation on protein-protein interactions

Single-cell proteomics:

• Emerging technologies enable protein and phosphoprotein analysis at single-cell resolution

• Can reveal heterogeneity in WEE1 phosphorylation status within populations

• Allows correlation of phospho-WEE1 levels with cell cycle phase and other parameters

Spatial proteomics:

• Imaging mass cytometry or multiplexed ion beam imaging can localize phospho-WEE1 in tissue contexts

• Preserves spatial relationships between phospho-WEE1 and other signaling molecules

• Provides insights into microenvironmental influences on WEE1 phosphorylation